Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer
This study aimed to identify the clinico-pathological variables predictive of radiologic complete response (rCR) to first-line anti-HER2 therapy in patients with HER2-positive metastatic breast cancer. Patients were selected from the database of the GIM14 study and classified according to the best radiologic response obtained to first-line anti-HER2 therapy and upon time-to-treatment-discontinuation (TTD). A total of 545 patients were included in the analysis. Eighty patients experienced a rCR to first-line anti-HER2 therapy with a TTD > 3 months and HER2 Immunohistochemistry score 3+, presence of non-visceral metastases and 1 metastatic site were significantly associated with higher odds of obtaining a CR. Of the 80 patients achieving a rCR, 56 experienced a CR with a TTD > 18 months, with anti-HER2 therapy being the only variable significantly associated with a higher probability of achieving such sustained CR.
Authors
- Arianna Dri (ORCID: https://orcid.org/0000-0002-6992-301X)
- Ferdinando Riccardi (ORCID: https://orcid.org/0000-0002-2852-2770)
- Fabio Puglisi (ORCID: https://orcid.org/0000-0003-0573-4938)
- Claudia Bighin
- Eva Blondeaux (ORCID: https://orcid.org/0000-0001-9566-4579)
- Michelino De Laurentiis (ORCID: https://orcid.org/0000-0001-9009-1572)
- Filippo Montemurro (ORCID: https://orcid.org/0000-0003-4231-2291)
- Simona Gasparro
- Grazia Arpino (ORCID: https://orcid.org/0000-0002-4074-2530)
- Alessandra Fabi (ORCID: https://orcid.org/0000-0002-0758-8033)
- Lorenzo Gerratana (ORCID: https://orcid.org/0000-0002-8313-4834)
- A. Ferzi (ORCID: https://orcid.org/0000-0002-8674-7062)
- Valentina Sini
- Lucia Del Mastro (ORCID: https://orcid.org/0000-0002-9546-5841)
- Stefania Russo (ORCID: https://orcid.org/0000-0003-0114-8042)
- Luca Boni (ORCID: https://orcid.org/0000-0003-2217-4047)
- Linda Cucciniello (ORCID: https://orcid.org/0009-0007-1270-0599)
- Enrico Cortesi (ORCID: https://orcid.org/0000-0002-8671-0155)
- Andrea Fontana (ORCID: https://orcid.org/0000-0003-2496-2506)
- Palma Pugliese
Institutions
- University of Udine (IT)
- Agostino Gemelli University Polyclinic (IT)
- Ospedale Antonio Cardarelli (IT)
- Ospedale Santa Maria della Misericordia di Udine (IT)
- Azienda Socio Sanitaria Territoriale Lariana (IT)
- Centro di Riferimento Oncologico (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Ospedale Policlinico San Martino (IT)
- Candiolo Cancer Institute (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Azienda Ospedaliera Ospedale Civile di Legnano (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Aziende Socio Sanitarie Territoriale Ovest Milanese
- University of Naples Federico II (IT)
- University of Genoa (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- npj Breast Cancer
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1038/s41523-024-00713-8
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Ministero della Salute